Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Assessing the measles immunity profile is critical for developing effective nationwide or regionwide supplementary immunization activities (SIAs). This study aims to assess measles population immunity levels in China and investigate factors contributing to age-specific heterogeneities.
Methods: We conducted a cross-sectional population-based serological study in southern China between June and October 2021. We determined the population mean antibody concentration and seroprevalence by age and over time, along with their associated determinants. Moreover, we estimated the contact-adjusted immunity levels by considering both age-specific immunity levels and population contact rates.
Results: Among the 1015 study participants (aged 0-95 years), the overall seroprevalence was estimated at 80.9% (95% confidence interval [CI], 78.3-83.3). When adjusting for the age-specific contact rates, the contact-adjusted immunity was estimated at 66.8% (95% CI, 56.6-75.1). Individuals younger than age 30 years showed significantly lower antibody concentration and seroprevalence (mean log concentration: 5.9, seroprevalence: 73.6% [95% CI, 69.9-77.3]) compared to those older than age 50 years (mean log concentration: 6.8, seroprevalence: 96.8% [95% CI, 94.7-98.9]). In particular, individuals born after the last SIA (2010) showed a significantly faster waning of immunity.
Conclusions: Our findings highlight that immunity levels in the general population remain below the 95% threshold, underscoring the need for continued monitoring of immunity dynamics, especially for individuals born in a near-elimination setting and without subsequent SIAs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039485 | PMC |
| http://dx.doi.org/10.1093/ofid/ofaf216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.
Pharmacoeconomics
September 2025
Department of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.
Background: Immune checkpoint inhibitors (ICIs) are clinically beneficial but associated with high costs that represent a growing challenge for healthcare budgets and may affect affordability, especially in resource-limited settings. Moreover, the healthcare sector is a significant source of greenhouse gas emissions, and medication-related waste-such as that from vial-based therapies-has been identified as a contributing factor. Alternative dosing strategies could reduce the environmental and financial impact of ICI therapy while maintaining clinical safety and efficacy.
View Article and Find Full Text PDFLactate and Lactylation in Respiratory Diseases: from Molecular Mechanisms to Targeted Strategies.
Lung
September 2025
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Introduction: Lactate has emerged as a multifunctional signaling molecule regulating various physiological and pathological processes. Furthermore, lactylation, a newly identified posttranslational modification triggered by lactate accumulation, plays significant roles in human health and diseases. This study aims to investigate the roles of lactate/lactylation in respiratory diseases.
View Article and Find Full Text PDFHLA Class Ib and MICA/MICB Expression in Human Tissues and Cell Types: Reshuffling Immune Players.
HLA
September 2025
Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France.
Abnormal expression of HLA class Ib, MICA and MICB molecules is associated with the evolution of pathological conditions and clinical settings. Here, we use RNA-sequencing data from two publicly-available projects, from different human organs and tissues and at single-cell level, to present their transcriptional expression throughout the human body, in comparison to that of HLA class Ia, HLA class II, their costimulatory molecules, and the main HLA transcription factors. Our analyses for 21 target genes reveal that median gene expression differs by orders of magnitude and that the classical/non-classical HLA distinction is not absolute for overall expression.
View Article and Find Full Text PDFATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade.
Cancer Immunol Res
September 2025
Alligator Bioscience (Sweden), Lund, Sweden.
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promises for addressing these limitations across solid tumors. Here, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5 developed for immunotherapy of cancer using the Neo-X-Prime platform.
View Article and Find Full Text PDFInterferon-induced miR-7705 modulates the anti-virus activity of cholesterol 25-hydroxylase.
J Virol
September 2025
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin, China.
Unlabelled: Cholesterol 25-hydroxylase (CH25H), an interferon-stimulated gene (ISG), has been implicated in broad-spectrum antiviral immunity. Here, we identify CH25H as a potent suppressor of hepatitis B virus (HBV) replication that significantly outperforms IFN-α in reducing HBV DNA, pregenomic RNA (pgRNA), HBsAg, and HBeAg, without inducing cytotoxicity. However, CH25H is weakly expressed in hepatocytes and only modestly induced by type I interferon.
View Article and Find Full Text PDF